LUME BioNIS: a Biomarker Study of Nintedanib in Patients With NSCLC
A non-interventional biomarker study in patients with non-small cell lung cancer (NSCLC) of adenocarcinoma tumour histology eligible for treatment with nintedanib* (Vargatef®) plus docetaxel according to the approved label.
Trial CT.gov-Identifier: NCT02671422
Patients with locally advanced, metastatic or locally recurrent NSCLC of adenocarcinoma histology after failure of first-line chemotherapy
The study was not originally planned to include an immunotherapy pretreated subgroup. However, such patients were eligible and were enrolled as a result of changes in the treatment landscape
Nintedanib plus docetaxel is initiated and administered in accordance with the approved label
Available formalin-fixed and paraffin-embedded tumor tissue routinely obtained at diagnosis and/or at re-biopsy prior to first-line treatment initiation
Primary outcome measure:
Overall survival (OS) in relation to exploratory biomarker assessment, including general expression profile, tumor genomic alterations and protein analysis.
The LUME-BioNIS trial is a non-interventional biomarker study in patients who are eligible to receive nintedanib plus docetaxel as part of routine treatment and according to the approved label, i.e. have advanced adenocarcinoma NSCLC after failure of first-line chemotherapy. Mutation analysis of nintedanib target genes will be conducted, as well as evaluation of tumor protein expression and proliferation markers by immunohistochemistry. The study was conducted at 86 European sites and has finished recruitment.
Patients previously treated with immunotherapy: LUME-BioNIS
In a subgroup analysis of patients previously treated with immunotherapy and chemotherapy (n=67), patients treated with nintedanib plus docetaxel had a median PFS of 4.6 months and a median OS of 8.8 months. The majority of patients (n=57; 85.1%) received nintedanib plus docetaxel as third- or later-line treatment, with 47 (70.1%) patients receiving prior immunotherapy as second- or later- line therapy.
OS outcomes for patients previously treated with immunotherapy and chemotherapy (n=67) in LUME-BioNIS
CI, confidence interval; OS, overall survival.
PFS outcomes for patients previously treated with immunotherapy and chemotherapy (n=67) in LUME-BioNIS
CI, confidence interval; PFS, progression-free survival.
Among 55 patients with available tumor response data, best response was partial response in 10 patients (18.2%) and stable disease in 33 patients (60.0%), providing a disease control rate of 78.2%.
Safety findings were consistent with the known safety profile of nintedanib plus docetaxel in patients with advanced NSCLC. The most common reported adverse event was diarrhea in 32.3% (21/65) of patients.
This subgroup analysis suggests that, when used in line with the approved nintedanib label in routine practice, nintedanib plus docetaxel can be clinically effective in patients with adenocarcinoma NSCLC previously treated with chemotherapy and first- or later-line immunotherapy.
Reck M, et al. Poster presented at ESMO I-O 2019 (Poster 80P).
Clinicaltrials.gov. https://clinicaltrials.gov/ct2/show/NCT02671422 (Accessed: June 2020).
*Nintedanib is approved in the EU under the brand name VARGATEF® for use in combination with docetaxel in adult patients with locally advanced, metastatic or locally recurrent NSCLC of adenocarcinoma tumor histology after first-line chemotherapy. For the full list of country-specific information, please click here. Nintedanib is not approved in other oncology indications.
© 2020 Boehringer Ingelheim International GmbH. All rights reserved.
Last updated: August 2020
Some links in this area will let you leave Boehringer Ingelheim's site and visit external websites. If not indicated otherwise in the imprint of the external website, the linked sites are not under the control of the Boehringer Ingelheim corporation and no entity of the Boehringer Ingelheim group of companies is responsible for the contents of such linked site or any link contained in such linked site, or any changes or updates to such sites. Neither is any entity of the Boehringer Ingelheim group of companies responsible for webcasting or any other form of transmission received from any linked site. These links are provided to you only as a convenience, and the inclusion of any link does not imply endorsement by the Boehringer Ingelheim group of companies of the site. In particular, Boehringer Ingelheim is not in a position to monitor the linked third party websites completely and permanently for violations of the law. Boehringer Ingelheim therefore accepts no responsibility for the accuracy or any other aspect of the information on this website. Boehringer Ingelheim is liable, if at all, only to the extent that it was aware of illegal content and it was technically possible and reasonable to prevent its use. The data protection declaration for this website does not apply to such linked websites.
Do you want to continue ?Continue